Tuesday, November 29, 2022
Home Tags NanoViricides

Tag: NanoViricides

Shelton’s NanoViricides moves forward with studies of possible Covid treatment

The company intends to perform certain core safety pharmacology studies to ensure safety of the drug candidate at Calvert Labs.

Shelton’s NanoViricides announces progress on clinical drug treatment for Covid-19

The company is working to complete the necessary required safety pharmacology studies that would allow it to apply to the FDA for permission to begin human clinical trials.

Shelton pharma company’s shingles treatment ready for human clinical trials

NanoViricides' first drug, NV-HHV-101, is a potential dermal treatment for the shingles virus.

Shelton’s NanoViricides reaches license agreement on shingles virus drug development

TheraCour Pharma would receive $4 million in milestone payments with the successful completion of Phase I and II human clinical trials.

New CEO at NanoViricides

Irach Taraporewala replaces Eugene Seymour, the Shelton-based company’s co-founder, who resigned earlier this year and is now CEO Emeritus.